Table 1. Characteristics of included studies.
| Study | Year | Cancer type | LINC00152 expression | LINC00152 assay | HR statistic | HR (95% CI) high/low | NOS | Cut-off value | Follow-up (months) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | |||||||||||||
| Total | LNM | III/IV | Total | LNM | III/IV | |||||||||
| Feng [16] | 2017 | LC | 51 | - | - | 50 | - | - | qRT-PCR | Survival curve | 2.04 (0.93–4.48) | 8 | ROC | 60 |
| Chen [11] | 2017 | LAD | 30 | 25 | 22 | 30 | 5 | 8 | qRT-PCR | Survival curve | 2.16 (0.77–6.03) | 8 | Median ratio | 40 |
| Wu [13] | 2016 | ccRCC | 38 | - | - | 39 | - | - | qRT-PCR | Date in paper | 2.58 (1.23–5.39) | 7 | - | > 60 |
| Wang [17] | 2017 | RCC | 27 | 19 | 21 | 18 | 7 | 6 | qRT-PCR | Survival curve | 1.98 (0.66–5.89) | 8 | Median ratio | > 60 |
| Cai [14] | 2016 | GBC | 23 | 15 | 17 | 17 | 5 | 6 | qRT-PCR | - | - | 8 | Ratio of T/N (2) | - |
| Yu [15] | 2017 | TSCC | 95 | 45 | 90 | 87 | 28 | 73 | qRT-PCR | Survival curve | 2.67 (1.38–5.33) | 7 | a | > 60 |
| Chen [12] | 2015 | GC | 59 | 43 | 28 | 48 | 34 | 16 | qRT-PCR | Date in paper | 1.66 (1.01–2.73) | 8 | ROC | > 60 |
| Cai [18] | 2016 | GBC | 18 | 6 | 9 | 17 | 5 | 13 | qRT-PCR | Survival curve | 2.53 (0.80–8.01) | 7 | Median ratio | 40 |
| Deng [19] | 2017 | HCC | 38 | - | 18 | 34 | - | 9 | qRT-PCR | Survival curve | 1.63 (0.96–2.79) | 7 | - | > 60 |
| Li [20] | 2015 | HCC | 33 | - | 14 | 33 | - | 2 | qRT-PCR | - | - | 8 | Median ratio | - |
Note: The dashes represent no data.
aA semi-quantitative scoring criterion for in situ hybridization was used in Yu's study. The final scores were regarded as low expression (0–1) and high expression (2–3).
III/IV: TNM grade III/IV; LNM: lymph node metastasis; LC: lung cancer; LAD: lung adenocarcinoma; ccRCC: clear cell renal cell carcinoma; RCC: renal cell carcinoma; GBC: gallbladder cancer; TSCC: tongue squamous cell carcinoma; GC: gastric cancer; HCC: hepatocellular carcinoma.